SCLERO.ORG
Search
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Autoimmune
Media Stories
Scleroderma
ISN/Website
Scleroderma Archive
We maintain news archives for the most recent 3 years.
2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2019 - 2018 - 2017 - 2016

September 2018 Scleroderma News

Case Report: Systemic scleroderma–related interstitial pneumonia associated with borderline pulmonary arterial hypertension. The clinical condition improved dramatically with a combination therapy of an antifibrotic agent, pirfenidone for 12 months, and the dual endothelin receptor antagonist, macitentan, with prednisolone. PubMed, BMJ Case Rep. (Also see Treatments for Pulmonary Hypertension)

Risk Factors for Future Scleroderma Renal Crisis (SRC) at Systemic Sclerosis Diagnosis. These patients may benefit from close observation of blood pressure, proteinuria, and estimated glomerular filtration rate, for earlier SRC identification and intervention. PubMed, J Rheumatol, 07/15/2018. (Also see Kidney (Renal) Involvement)

TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung. The results suggest that systemic scleroderma patients with high TLR4 activity might show optimal therapeutic response to selective inhibitors of MD2/TLR4 complex formation. PubMed, JCI Insight, 2018 Jul 12;3(13). (Also see Fibroblasts, Skin Fibrosis and Pulmonary Fibrosis Research)

Anti-CCP antibodies and rheumatoid factor (RF) in systemic sclerosis: Prevalence and relationships with joint manifestations. The prevalence of RF and anti-CCP antibodies is relatively high in SSc, and joint involvement occurs frequently. PubMed, Adv Clin Exp Med, 07/19/2018. (Also see Antibodies and Rheumatoid Arthritis in Overlap)

Insights into myofibroblasts and their activation in scleroderma: opportunities for therapy? This review outlines the increasing complexity of the biological processes that leads to the appearance of the myofibroblast in normal functions and in diseased tissues. PubMed, Curr Opin Rheumatol, 07/31/2018. (Also see Fibroblasts)

High Prevalence of Antithyroid Antibodies (ATAs) in a New Zealand Cohort of Patients With Systemic Sclerosis (SSc). There is a higher prevalence of ATAs in SSc and Ssc– overlap syndrome compared with the general population and screening these patients for ATAs is a reasonable measure. PubMed, J Clin Rheumatol, 2018 Aug;24(5):264-271. (Also see Antibodies and Thyroid Diseases)

Evaluation of Vitamin B12 Deficiency and Associated Factors in Patients With Systemic Sclerosis (SSc). Vitamin B12 deficiency is frequent in SSc and has multiple causes and all patients should be monitored for Vitamin B12 deficiency. PubMed, J Clin Rheumatol, 2018 Aug;24(5):250-254. (Also see Supplement Guide for Systemic Scleroderma)

Synovial involvement assessed by power Doppler ultra–sonography (PDUS) in systemic sclerosis: results of a cross–sectional study. Ultrasonographic synovial involvement is frequent in patients and PDUS may have a part to play in a more accurate and precise description of musculoskeletal manifestations of the disease. PubMed, Rheumatology (Oxford), 07/24/2018. (Also see Musculoskeletal Involvement)

The role of stress in the mosaic of autoimmunity. An overlooked association. Psychological therapy and cognitive behavioral therapy aimed to reduce stress levels was shown to be effective in influencing better outcomes in many autoimmune diseases. PubMed, Autoimmun Rev, 08/14/2018. (Also see Causes of Scleroderma: Stress)

Skin resident memory T cell population is not effectively constructed in systemic sclerosis. Regarding the contribution of circulating T cells, over–production of IL-13 by circulating effector/memory T cells is reported to be critical for more severe cutaneous disease. PubMed, Br J Dermatol, 08/18/2018. (Also see B Cells and T Cells)

Go to Scleroderma Medical News: August 2018
 

In Loving Memory of Lorraine Wempner, a donation to tackle scleroderma has been made by Paul Wempner. Posted 11/13/2019. (Also see: ISN News)

We have the world's best supporters! See ISN News.

 

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.
 

The most important thing in the world to know about scleroderma is sclero.org!